drugset / Trial / NCT07713485
Study of XmAb412 in Healthy Participants
RandomizedSequentialDouble-blindTreatment
Summary
This Phase 1 Study will evaluate the safety, tolerability, pharmacokinectics and pharmacodynamics of XmAb412 in healthy adult participants
Timeline
- Start
- 2026-07-13
- Primary completion
- 2027-05
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | XmAb412 | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.